Article
Medicine, General & Internal
Hiroyoshi Mori, Takuya Mizukami, Atsuo Maeda, Kazuki Fukui, Yoshihiro Akashi, Junya Ako, Yuji Ikari, Toshiaki Ebina, Kouichi Tamura, Atsuo Namiki, Ichiro Michishita, Kazuo Kimura, Hiroshi Suzuki
Summary: The 1-year rates of ischemic and bleeding events were similar in Japanese patients with AMI treated with prasugrel or clopidogrel.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Francesco Franchi, Fabiana Rollini, Luis Ortega-Paz, Latonya Been, Salvatore Giordano, Mattia Galli, Ghussan Ghanem, Haroutioun Garabedian, Tala Al Saleh, Ekin Uzunoglu, Andrea Rivas, Andres M. Pineda, Siva Suryadevara, Daniel Soffer, Martin M. Zenni, Madeline Mahowald, Birgit Reiter, Bernd Jilma, Dominick J. Angiolillo
Summary: This study compared the effects of concomitant administration of cangrelor and prasugrel with prasugrel alone in patients undergoing percutaneous coronary intervention (PCI). The results showed that concomitant administration of cangrelor and prasugrel led to a marked increase in platelet reactivity after stopping cangrelor infusion, indicating the presence of a drug-drug interaction.
JACC-CARDIOVASCULAR INTERVENTIONS
(2023)
Article
Hematology
Luis Ortega-Paz, Francesco Franchi, Fabiana Rollini, Mattia Galli, Latonya Been, Ghussan Ghanem, Awss Shalhoub, Tiffany Ossi, Andrea Rivas, Xuan Zhou, Andres M. Pineda, Siva Suryadevara, Daniel Soffer, Martin M. Zenni, Lisa K. Jennings, Dominick J. Angiolillo
Summary: This study aimed to assess the feasibility of switching from dual antiplatelet therapy (DAPT) to dual pathway inhibition (DPI) and compare the pharmacodynamic (PD) profiles of these treatments. The results showed that switching from various DAPT regimens to DPI was feasible in patients with chronic coronary syndrome (CCS), with enhanced P2Y(12) inhibition with DAPT and reduced thrombin generation with DPI. There were no differences in platelet-mediated global thrombogenicity between DPI and ticagrelor- and prasugrel-based DAPT, but differences were observed with clopidogrel-based DAPT.
THROMBOSIS AND HAEMOSTASIS
(2023)
Article
Cardiac & Cardiovascular Systems
Emanuela Marcantoni, Michael S. Garshick, Tamar Schwartz, Nicole Ratnapala, Matthew Cambria, Rebecca Dann, Meagan O'Brien, Adriana Heguy, Jeffrey S. Berger
Summary: Clopidogrel, compared with aspirin and no-treatment, reduces platelet activation and the risk of cardiovascular disease in HIV-positive patients.
JACC-BASIC TO TRANSLATIONAL SCIENCE
(2022)
Article
Hematology
Freek W. A. Verheugt, Kurt Huber, Peter Clemmensen, Jean-Philippe Collet, Thomas Cuisset, Felicita Andreotti
Summary: Antiplatelet therapy is crucial for preventing secondary ischemic heart disease. After PCI, temporary DAPT, which consists of aspirin and an oral P2Y12 receptor blocker, is recommended. However, long-term DAPT increases the risk of bleeding compared to aspirin monotherapy. To reduce bleeding, shorter DAPT duration or switching to P2Y12 inhibitor monotherapy have been suggested. This survey reviews the evidence and provides clinical guidance on the use of P2Y12 inhibitor monotherapy after DAPT cessation following PCI.
THROMBOSIS AND HAEMOSTASIS
(2023)
Letter
Medicine, General & Internal
John A. Bittl
Summary: The article discusses the preference for antithrombotic therapy in patients with acute coronary syndromes and the difference between preference and actual practice. It also mentions a new study, but does not explicitly state whether this new study can explain the discrepancy.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Pharmacology & Pharmacy
Georges Jourdi, Guillaume Marquis-Gravel, Anne-Celine Martin, Marie Lordkipanidze, Anne Godier, Pascale Gaussem
Summary: Antiplatelet therapy, including aspirin and P2Y(12) receptor antagonists, is essential for the treatment and prevention of atherothrombotic diseases. Bleeding complications remain a major concern, but guidelines provide practical recommendations for clinicians. However, there are variations in strategies across countries regarding drug choice, dosage, and treatment duration.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Shqipdona Lahu, Gjin Ndrepepa, Franz-Josef Neumann, Maurizio Menichelli, Isabell Bernlochner, Gert Richardt, Jochen Wohrle, Bernhard Witzenbichler, Rayyan Hemetsberger, Katharina Mayer, Ibrahim Akin, Salvatore Cassese, Senta Gewalt, Erion Xhepa, Sebastian Kufner, Christian Valina, Hendrik B. Sager, Michael Joner, Tareq Ibrahim, Karl-Ludwig Laugwitz, Heribert Schunkert, Stefanie Schupke, Adnan Kastrati
Summary: Pre-admission treatment with aspirin and/or clopidogrel does not affect the efficacy and safety of ticagrelor and prasugrel in patients with acute coronary syndromes.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2022)
Review
Medicine, General & Internal
Elisa Bellettini, Leonardo De Luca
Summary: Patients with CAD and prior CVE present a high risk of both ischemic and bleeding events, making antithrombotic management challenging. Balancing the risks of ischemia and bleeding is crucial, especially when considering long-term antithrombotic therapy to prevent major bleeding complications.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Hematology
Jonathan H. Chow, Ying Yin, David P. Yamane, Danielle Davison, Ryan J. Keneally, Katrina Hawkins, K. Gage Parr, Mustafa Al-Mashat, Jeffery S. Berger, Reamer L. Bushardt, Michael A. Mazzeffi, Stuart J. Nelson
Summary: A large observational study of COVID-19 patients found that prehospital antiplatelet therapy was associated with significantly lower in-hospital mortality. The study suggests that further randomized controlled trials are needed to determine the ultimate utility of antiplatelet therapy in COVID-19 patients with high rates of comorbidities.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2021)
Article
Pharmacology & Pharmacy
Georg Gelbenegger, Ummahan Erari-Canyurt, Jurgen Grafeneder, Bernd Jilma, Maciej Lesiak, Anna Komosa, Raffaele de Caterina, Marek Postula, Jolanta M. Siller-Matula
Summary: This study suggests that very short-term DAPT after PCI does not increase the risk of MACE, while any longer-term DAPT can significantly reduce the risk of MACE, but may increase the risk of major bleeding.
VASCULAR PHARMACOLOGY
(2021)
Review
Pharmacology & Pharmacy
Marharyta Kamarova, Sheharyar Baig, Hamish Patel, Kimberley Monks, Mohammed Wasay, Ali Ali, Jessica Redgrave, Arshad Majid, Simon M. Bell
Summary: The literature review examines the use of antiplatelet agents for primary and secondary stroke prevention, including mechanism of action, cost, and reasons for lack of benefit. The review finds strong evidence supporting the use of aspirin and clopidogrel for secondary stroke prevention, but highlights the increased risk of hemorrhage with long-term combination therapy. Poor adherence and genetic polymorphisms are identified as factors contributing to antiplatelet treatment failure. The review also suggests that certain antiplatelet agents, such as cilostazol, may provide additional benefits in specific racial groups, but further research in diverse populations is needed. Overall, the review emphasizes the need for personalized therapies and future research in this field.
ANNALS OF PHARMACOTHERAPY
(2022)
Review
Medicine, General & Internal
Hassan Kamran, Hani Jneid, Waleed T. Kayani, Salim S. Virani, Glenn N. Levine, Vijay Nambi, Umair Khalid
Summary: Dual antiplatelet therapy is beneficial for patients with acute coronary syndrome, and the specific combination and duration should be based on patient characteristics and bleeding risk.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Cardiac & Cardiovascular Systems
Ilaria Cavallari, Giuseppe Patti, Ernesto Maddaloni, Francesco Veneziano, Fabio Mangiacapra, Elisabetta Ricottini, Raffaella Buzzetti, Gian Paolo Ussia, Francesco Grigioni
Summary: This study investigated the role of low platelet reactivity (LPR) in the bleeding risk stratification of patients who underwent percutaneous coronary intervention (PCI) according to their diabetes mellitus (DM) status. The results showed that LPR provided significant incremental value for predicting bleeding, regardless of DM status. The coexistence of DM and LPR identified the subgroup with the highest bleeding risk.
AMERICAN JOURNAL OF CARDIOLOGY
(2022)
Article
Clinical Neurology
Jing Jing, Xuewei Xie, S. Claiborne Johnston, Philip M. Bath, Zixiao Li, Xingquan Zhao, Liping Liu, Yilong Wang, Qin Xu, Anxin Wang, Yong Jiang, Hao Li, Xia Meng, Yongjun Wang
Summary: This study investigates whether ticagrelor/aspirin can further reduce the risk of stroke recurrence in patients with positive diffusion-weighted imaging (DWI) compared to clopidogrel/aspirin. The results show that ticagrelor/aspirin is associated with a lower risk of stroke in patients with positive DWI compared to clopidogrel/aspirin. Therefore, imaging evaluation should be emphasized in future clinical research and practice to target the best candidates for genotype-guided dual antiplatelet therapy.
ANNALS OF NEUROLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Robert G. Hart, Aristeidis H. Katsanos, Kanjana S. Perera, John W. Eikelboom
Summary: This study evaluated randomized clinical trials testing oral factor Xa inhibitors for prevention of ischemic stroke in patients without AF. The results showed that compared to placebo and aspirin, oral factor Xa inhibitors can reduce ischemic stroke in patients without AF, but they also increase the risk of major bleeding.
CANADIAN JOURNAL OF CARDIOLOGY
(2023)
Review
Cardiac & Cardiovascular Systems
Raffaele De Caterina, Domenico Prisco, John W. Eikelboom
Summary: This paper reviews the potential of drugs targeting factor XI in anticoagulant therapy, along with ongoing clinical trials and future research directions.
EUROPEAN HEART JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Thomas Jensen, Pernille G. Thrane, Kevin K. W. Olesen, Morten Wurtz, Martin Bodtker Mortensen, Christine Gyldenkerne, Troels Thim, Bjarne Linde Norgaard, Jesper Moller Jensen, Steen Dalby Kristensen, Jens C. Nielsen, John W. Eikelboom, Michael Maeng
Summary: The study compared the risks of bleeding and ischemic events in patients with atrial fibrillation (AF) treated with anticoagulant monotherapy or dual therapy after 1 year of percutaneous coronary intervention (PCI). The results showed that the risks were similar between monotherapy and dual therapy, as well as between DOAC and VKA monotherapy.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2023)
Article
Cardiac & Cardiovascular Systems
Ziad Hijazi, Alexander P. Benz, Johan Lindback, John H. Alexander, Stuart J. Connolly, John W. Eikelboom, Christopher B. Granger, Peter Kastner, Renato D. Lopes, Andre Ziegler, Jonas Oldgren, Agneta Siegbahn, Lars Wallentin
Summary: In this study, BMP10 may be a novel specific biomarker of ischaemic stroke in patients with atrial fibrillation, irrespective of oral anticoagulation.
EUROPEAN HEART JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Tjerk S. J. Opstal, Stefan M. Nidorf, Aernoud T. L. Fiolet, John W. Eikelboom, Arend Mosterd, Willem A. Bax, Charley A. Budgeon, Eelko Ronner, Fransisco J. Prins, Jan G. P. Tijssen, Astrid Schut, Peter L. Thompson, Saloua El Messaoudi, Jan H. Cornel
Summary: Low-dose colchicine reduces the risk of cardiovascular events in patients with chronic coronary disease. However, concerns about non-cardiovascular death have been raised. This study analyzed cause-specific mortality and predictors of mortality in the LoDoCo2 trial.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2023)
Article
Hematology
Jack Hirsh, Tim A. C. de Vries, John W. Eikelboom, Vinai Bhagirath, Noel C. C. Chan
Summary: Anticoagulant therapy is crucial for treating and preventing blood clots. This article discusses important clinical trials of anticoagulants from the 1960s to 2022 and explores the challenges in bringing these drugs to the clinic. Early studies had flaws in design but were influential due to the lack of alternatives. Heparin and vitamin K antagonists were optimized in the 1980s, and later, low-molecular-weight heparin and direct oral anticoagulants became preferred options.
SEMINARS IN THROMBOSIS AND HEMOSTASIS
(2023)
Editorial Material
Hematology
John W. Eikelboom, Jeffrey I. Weitz
THROMBOSIS AND HAEMOSTASIS
(2023)
Article
Cardiac & Cardiovascular Systems
Jr Tuman J. Milling, Saskia Middeldorp, Lizhen Xu, Bruce Koch, Andrew Demchuk, John W. Eikelboom, Peter Verhamme, Alexander T. Cohen, Jan Beyer-Westendorf, C. Michael Gibson, Jose Lopez-Sendon, Mark Crowther, Ashkan Shoamanesh, Michiel Coppens, Jeannot Schmidt, Pierre Albaladejo, Stuart J. Connolly
Summary: This study evaluated the safety and efficacy of andexanet alfa in patients with major bleeding caused by factor Xa inhibitors. The results showed that the drug reduced anti-FXa activity and achieved good or excellent hemostatic efficacy in 80% of the patients.
Article
Cardiac & Cardiovascular Systems
Alexander P. Benz, Stefan H. Hohnloser, John W. Eikelboom, Anthony P. Carnicelli, Robert P. Giugliano, Christopher B. Granger, Josephine Harrington, Ziad Hijazi, David A. Morrow, Manesh R. Patel, David J. Seiffge, Ashkan Shoamanesh, Lars Wallentin, Qilong Yi, Stuart J. Connolly
Summary: This study aimed to investigate the prognosis of patients with atrial fibrillation (AF) and ischemic stroke while on oral anticoagulation. The results showed that among the 1163 patients who had a post-randomization ischemic stroke while on study medication, 7.0% had a recurrent ischemic stroke within 1 year, and the all-cause mortality rate within 3 months was 12.4%.
EUROPEAN HEART JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Darryl Wan, Mahshid Dehghan, Russell J. de Souza, Chinthanie Ramasundarahettige, John W. Eikelboom, Jackie Bosch, Aldo P. Maggioni, Deepak L. Bhatt, Salim Yusuf, Sonia S. Anand
Summary: This study examined the association between dietary patterns and the risk of recurrent major adverse cardiovascular and limb events in patients with coronary artery disease (CAD) and peripheral artery disease (PAD). The findings suggest that poor diet quality is independently associated with a higher risk of such events.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2023)
Editorial Material
Cardiac & Cardiovascular Systems
Stephanie Carlin, John Eikelboom
EXPERT REVIEW OF CARDIOVASCULAR THERAPY
(2023)
Article
Cardiac & Cardiovascular Systems
Ziad Hijazi, Johan Lindbaeck, Jonas Oldgren, Alexander P. Benz, John H. Alexander, Stuart J. Connolly, John W. Eikelboom, Christopher B. Granger, Renato D. Lopes, Agneta Siegbahn, Lars Wallentin
Summary: This study evaluated the net clinical outcome of oral anticoagulation (OAC) in patients with atrial fibrillation (AF) and identified clinically relevant thresholds for OAC treatment decisions. The findings showed that OAC treatment provides greater net clinical benefit than no-OAC treatment in patients with higher stroke risk, while a balanced decision is needed for patients with lower stroke risk.
AMERICAN HEART JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Alexander P. Benz, Ziad Hijazi, Johan Lindbaeck, Stuart J. Connolly, John W. Eikelboom, Peter Kastner, Andre Ziegler, John H. Alexander, Christopher B. Granger, Renato D. Lopes, Jonas Oldgren, Agneta Siegbahn, Lars Wallentin
Summary: This study aimed to evaluate the role of angiopoietin-2 in patients with atrial fibrillation (AF). The results showed that plasma angiopoietin-2 was independently associated with AF and various risk factors, such as heart failure, age, and smoking. Furthermore, plasma angiopoietin-2 could predict the risk of hospitalization for heart failure in AF patients. Therefore, angiopoietin-2 may be a promising biomarker for AF.
Article
Cardiac & Cardiovascular Systems
Pascal M. Burger, Jannick A. N. Dorresteijn, Aernoud T. L. Fiolet, Stefan Koudstaal, John W. Eikelboom, Stefan M. Nidorf, Peter L. Thompson, Jan H. Cornel, Charley A. Budgeon, Iris C. D. Westendorp, Driek P. W. Beelen, Fabrice M. A. C. Martens, Philippe Gabriel Steg, Folkert W. Asselbergs, Maarten J. Cramer, Martin Teraa, Deepak L. Bhatt, Frank L. J. Visseren, Arend Mosterd
Summary: A study found that low-dose colchicine treatment can lower the risk of cardiovascular disease in patients with coronary heart disease. It is estimated to reduce the risk from 17.8% to 13.2% in the next 10 years and provide an additional 2.0 years of life without cardiovascular disease. Low-dose colchicine was found to be the most effective treatment in 49% of patients, compared to intensive blood pressure-lowering therapy in 28% and intensive lipid-lowering therapy in 23%.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2023)
Article
Hematology
John W. Eikelboom, Jeffrey I. Weitz
Summary: Although DOACs are preferred over VKAs for stroke prevention in most patients with AF, they are not recommended for those with rheumatic heart disease or mechanical heart valves. Results from the INVICTUS and PROACT Xa trials support the use of VKAs for these specific indications. This paper reviews the findings from these trials, provides insights into why VKAs were superior to DOACs, and discusses future directions for anticoagulation in these disorders.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2023)
